| References | Drug Study | Design | Evidence level | Dose | Age(years) | Number of patients | Responders (%) Active drug |
Responders (%) Placebo |
p value |
| Hamalainen et al 1997 | Ibuprofen | RCT | A | 10 mg/kg | 4–16 | 88 | 68 | 37 | <0.05< /td> |
| Lewis et al 2002 | Ibuprofen | RCT | 7.5 mg/kg | 6–12 | 84 | 76 | 53 | 0.006 | |
| Evers et al 2006 | Ibuprofen | RCT | 200–400 mg | 6–18 | 32 | 69 | 28 | <0.05< /td> | |
| Hamalainen 1997 | Acetaminophen | RCT | B | 15 mg/kg | 4–16 | 88 | 54 | 37 | <0.05< /td> |
| Hamalainen et al 1997 | Dihydroergotamine | RCT | C | 20,40 microg/kg | 5–15 | 12 | 58 | 16 | NS |
| Ueberall 1999 | Sumatriptan nasal | RCT | A | 20 mg | 6–10 | 14 | 86 | 43 | 0.03 |
| Winner et al. 2001 | Sumatriptan nasal | RCT | 5–10–20 mg | 12–17 | 510 | 66* | 53 | <0.05< /td> | |
| Ahonen et al. 2004 | Sumatriptan nasal | RCT | 10–20 mg | 8–17 | 83 | 64 | 39 | 0.003 | |
| Winner et al. 2006 | Sumatriptan nasal | RCT | 20 mg | 12–17 | 738 | 61 | 52 | NS | |
| Hamalainen et al. 1997 | Sumatriptan oral | RCT | C | 50–100 mg | 8–16 | 23 | 30 | 22 | NS |
| Mac Donald 1994 | Sumatriptan sc. | OT | C | 3–6 mg | 6–16 | 17 | 64 | – | – |
| Linder 1996 | Sumatriptan sc. | OT | 0.06 mg/kg | 6–18 | 50 | 78 | – | - | |
| Winner et al. 2002 | Rizatriptan | RCT | C | 5 mg | 12–17 | 196 | 66 | 56 | NS |
| Visser et al. 2004 | Rizatriptan | RCT | 5 mg | 12–17 | 234 | 68 | 69 | NS | |
| Visser et al. 2004 | Rizatriptan | OT | 5 mg | 12–17 | 686 | 77 | – | – | |
| Linder and Dowson 2000 | Zolmitriptan oral | OT | C | 2.5–5 mg | 12–17 | 38 | 88–70 | – | – |
| Evers et al. 2006 | Zolmitriptan oral | RCT | 2.5 mg | 6–18 | 32 | 62 | 28 | <0.05< /td> | |
| Charles 2006 | Almotriptan oral | OT | B | 6.25–12.5 mg | 11–17 | 15 | 86 | – | – |
| Linder et al. 2008 | Almotriptan oral | RCT | 6.25–12.5–25 mg | 12–17 | 866 | 67–73 | 55 | <0.001< /td> |
Evidence level
- Level A: two or more clinically controlled, randomized studies carried out according to good clinical practice (GCP), versus placebo or versus active treatment of proven efficacy.
- Level B: one clinically controlled, randomized study carried out according to GCP or more than one well-designed clinical case–control study or cohort study
- Level C: favourable judgment of two-third of the Ad Hoc Committee members, historical controls, non-randomized studies, case reports
- NS no statistically significant difference between active drug and placebo, RCT randomized controlled trial, OT open trial
*5 mg
Migraine prophylaxis
Cite this: ICNApedia contributors.Symptomatic drugs for migraine management evaluated in placebo-controlled and open clinical trials. ICNApedia, The Child Neurology Knowledge Environment. 24 November 2024. Available at: https://icnapedia.org/knowledgebase/articles/symptomatic-drugs-for-migraine-management-evaluated-in-placebo-controlled-and-open-clinical-trials Accessed 24 November 2024.
